Editorial: Proof of Concept
The recent announcement of the Phase II proof-of-concept efficacy trial of Merck’s replication-defective adenovirus vector vaccine candidate, MRK-Ad5, is a very important step for the AIDS vaccine field.
Vol. 08, No. 2, May-Aug. 2004
Serodiscordant couples, Proof of Concept, Early dendritic cell-driven events governing the mucosal transmission of HIV, Microbicides in the Spotlight, Perspective: Microbicides Come of Age?, Vaccine Briefs, Research Briefs
Microbicides in the Spotlight
Recent meetings highlight this young field, and its many points of convergence with AIDS vaccines
Perspective: Microbicides Come of Age?
By Robin J. Shattock, Ph.D.*
Growing up can be a painful business, especially when the optimism of youth is tempered by the reality of experience.
Research Briefs
By Roberto Fernandez-Larsson, Ph.D.*
Env immunogens contribute to AIDS vaccine protection in simian models
Review: Early dendritic cell-driven events governing the mucosal transmission of HIV: targets for vaccines and microbicides
By Melissa Pope, Ph.D.*
HIV breaches mucosal barriers as either cell-free or cell-associated virus, subsequently interacting with local leukocytes within the tissues to establish infection.
Serodiscordant couples: Africa’s largest HIV at-risk group
An Interview with Dr. Susan Allen
Vaccine Briefs
G8 endorses plan to accelerate AIDS vaccine development